Biotech Business Advises on Clinical Collaboration Agreement with Merck

Biotech Business Advises on Clinical Collaboration Agreement with Merck (MSD)

August - 2016

Biotech Business’s client, Biothera Pharmaceuticals Inc., Eagan MN (www.biothera.com) announced today a clinical collaboration with Merck (NYSE:MRK), known as MSD outside the USA and Canada. The collaboration will evaluate the combination of Biothera’s innate immune modulator, Imprime PGG, with Merck’s checkpoint inhibitor, pembrolizumab, in a phase 2 clinical study in patients with advanced melanoma or chemorefractory metastatic triple negative breast cancer. 

For more information see: 
https://www.biothera.com/biothera-pharmaceuticals-expands-relationship-with-merck-enters-collaboration-for-combination-cancer-immunotherapy-trials-in-multiple-indications/

Comments are closed.